Sharon O’Byrne

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

Séverine Vermeire, Sharon O’Byrne, Mary Keir et al. · The Lancet · 2014 · 453 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis

Gaik W. Tew, Jason A. Hackney, Deena L. Gibbons et al. · Gastroenterology · 2015 · 157 citations · Full text

Veterinary Medicine, Immunology, Pharmacology +17

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

Paul Rutgeerts, Richard N. Fedorak, Daan W. Hommes et al. · Gut · 2012 · 150 citations · Full text

Medicine, Immunology, Pharmacology +17

EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging

William A. Faubion, Joel G. Fletcher, Sharon O’Byrne et al. · The American Journal of Gastroenterology · 2013 · 109 citations

Medicine, Clinical Sciences, Immunology +17

αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis

Christopher A Lamb, John Mansfield, Gaik W. Tew et al. · Journal of Crohn s and Colitis · 2016 · 65 citations · Full text

Life Sciences, Immunology, Pathology +17